Background Information Of Gastric Cancer

The Necessity Of Detecting Chemotherapy Sensitivity Of Gastric Cancer

  • Among the world, gastric cancer is the fifth leading cause of cancer, and it ranks third in the cancer death rate ranking, accounting for 7% and 9% of cases respectively.The incidence and mortality of gastric cancer in China showed a downward trend, but the number of cases and the number of deaths still ranked second, just after lung cancer.




    In general, the average five-year survival rate of gastric cancer patients is about 22%, while the five-year survival rate of patients with advanced gastric cancer is less than 5%. Chemotherapy has become an indispensable method for the treatment of gastric cancer, and chemotherapy has been shown to improve survival or end-life quality.

    A number of studies have shown that the current clinical staging system for gastric cancer does not provide complete patient prognostic information and does not accurately predict which patients may benefit from adjuvant chemotherapy.

Gastric Cancer Chemotherapy Sensitivity Test

Currently We Offer Two Chemotherapy Sensitivity Tests For Gastric Cancer

  • AI Gastric – Clinical

    Prediction of the chemotherapy sensitivity in patients with stage 2 or 3 gastric cancer after surgery using routine clinical data

  • AI Gastric – Immunoscore

    Based on the pathomics technology, patient’s IHC stained pathological images are rapidly analyzed to generate an immune score for predicting the sensitivity of postoperative chemotherapy in patients with stage 2 and 3 gastric cancer.

    Coming Soon...



Jiang, Yuming, et al. "Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer." JAMA surgery 152.7 (2017): e171087-e171087.


Jiang, Yuming, et al. "ImmunoScore signature: a prognostic and predictive tool in gastric cancer." Annals of surgery 267.3 (2018): 504-513.

Exclusive Collaborations

  • We collaborate with General Surgery department of Southern Hospital in the field of gastric cancer, and are jointly developing innovative precision diagnostic tools for gastric cancer and to improve the clinical decision in the field of gastric cancer.